Written Questions are submitted by MPs or Lords to receive information from a Department.
|4 Dec 2017, 5:18 p.m.||Christopher Chope (Conservative - Christchurch)||Christopher Chope (Conservative - Christchurch)|
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the timetable is for a decision to be made on the authorisation of spinroza as an NHS treatment for people who suffer from spinal muscular atrophy; and if he will make a statement.
Answered by Steve Brine
We have assumed the hon. Member is referring to Spinraza. The National Institute for Health and Care Excellence (NICE) received a formal ministerial referral for nusinersen (Spinraza) to treat spinal muscular atrophy and this topic has been scheduled into its work programme. The appraisal process is anticipated to begin in January 2018 and the deadline for an evidence submission is anticipated to be March 2018. Although no further details about timescales for the development of guidance are available at this stage, NICE take approximately nine months to develop guidance on new drug depending on the individual product.